Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Alexandr O, Ivantsov"'
Autor:
Natalia V. Mitiushkina, Alexandr A. Romanko, Elena V. Preobrazhenskaya, Vladislav I. Tiurin, Tatiana I. Ermachenkova, Alexandr S. Martianov, Rimma S. Mulkidjan, Tatiana N. Sokolova, Maksim M. Kholmatov, Ilya V. Bizin, Alexandr O. Ivantsov, Olga S. Yatsuk, Olga A. Zaitseva, Aglaya G. Iyevleva, Ekatherina Sh. Kuligina, Evgeny N. Imyanitov
Publikováno v:
Cancer Medicine, Vol 11, Iss 17, Pp 3226-3237 (2022)
Abstract Background Despite the progress in the development of next‐generation sequencing (NGS), diagnostic PCR assays remain to be utilized in clinical routine due to their simplicity and low cost. Tests for 5′‐/3′‐end mRNA unbalanced expr
Externí odkaz:
https://doaj.org/article/d38a620319e847078e9a0ddad75d9206
Autor:
Tatiana V. Gorodnova, Anna P. Sokolenko, Khristina B. Kotiv, Tatiana N. Sokolova, Alexandr O. Ivantsov, Konstantin D. Guseynov, Ekaterina A. Nekrasova, Olga A. Smirnova, Igor V. Berlev, Evgeny N. Imyanitov
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 19, Iss 1, Pp 1-7 (2021)
Abstract Background Cisplatin, mitomycin C and anthracyclines demonstrate high activity in BRCA1-deficient tumors. This study aimed to evaluate the efficacy of the triplet combination of these drugs in BRCA1-driven high-grade serous ovarian carcinoma
Externí odkaz:
https://doaj.org/article/e6bae727d3b348d2a15b6c1b9e0e6d04
Autor:
Tatiana N. Sokolova, Valeriy V. Breder, Irina S. Shumskaya, Evgeny N. Suspitsin, Svetlana N. Aleksakhina, Grigoriy A. Yanus, Vladislav I. Tiurin, Alexandr O. Ivantsov, Barbara Vona, Grigoriy A. Raskin, Sergey V. Gamajunov, Evgeny N. Imyanitov
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 19, Iss 1, Pp 1-7 (2021)
Abstract Background Many cancer patients undergo sophisticated laboratory testing, which requires proper interpretation and interaction between different specialists. Case presentation We describe a patient with an extensive family history of cancer,
Externí odkaz:
https://doaj.org/article/7933bc51ad394e47ad71d5482a37d35d
Autor:
Sergey V. Orlov, Aglaya G. Iyevleva, Elena A. Filippova, Alexandra M. Lozhkina, Svetlana V. Odintsova, Tatiana N. Sokolova, Natalia V. Mitiushkina, Vladislav I. Tiurin, Elena V. Preobrazhenskaya, Alexandr A. Romanko, Alexandr S. Martianov, Alexandr O. Ivantsov, Svetlana N. Aleksakhina, Alexandr V. Togo, Evgeny N. Imyanitov
Publikováno v:
Translational Oncology, Vol 14, Iss 8, Pp 101121- (2021)
Background: Lorlatinib is a novel potent ALK inhibitor, with only a few studies reporting the results of its clinical use. Methods: This study describes the outcomes of lorlatinib treatment for 35 non-small cell lung cancer patients with ALK rearrang
Externí odkaz:
https://doaj.org/article/7a54773d24a54c3d9f4951da25379307
Autor:
Evgeny N Imyanitov, Ekaterina S Kuligina, Anna P Sokolenko, Evgeny N Suspitsin, Grigoriy A Yanus, Aglaya G Iyevleva, Alexandr O Ivantsov, Svetlana N Aleksakhina
Publikováno v:
World Journal of Clinical Oncology. 14:40-68
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b39caeddfe48fc7ae44d77f0393e39f7
https://doi.org/10.5306/wjco.v14.i2.40
https://doi.org/10.5306/wjco.v14.i2.40
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Comprehensive molecular testing plays a critical role in the choice of treatment for non-small lung cell cancer (NSCLC). The analysis of druggable alterations in EGFR, BRAF, MET, KRAS, ALK, ROS1, RET and NTRK1/2/3 genes is more or less standardized a
Externí odkaz:
https://doaj.org/article/30e0d8d00a4344cab7f0ca7a544c9561
Autor:
Aglaya G. Iyevleva, Svetlana N. Aleksakhina, Anna P. Sokolenko, Sofia V. Baskina, Aigul R. Venina, Elena I. Anisimova, Ilya V. Bizin, Alexandr O. Ivantsov, Yana V. Belysheva, Alexandra P. Chernyakova, Alexandr V. Togo, Evgeny N. Imyanitov
Publikováno v:
Breast Cancer Research and Treatment. 192:283-291
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e086ed9674dd019b4a58a45c41a69c91
https://doi.org/10.1007/s10549-022-06517-3
https://doi.org/10.1007/s10549-022-06517-3
Autor:
Anna P. Sokolenko, Fedor V. Moiseyenko, Aglaya G. Iyevleva, Alexandr O. Ivantsov, Georgiy D. Dolmatov, Ksenia V. Shelekhova, Elizaveta V. Gulo, Anastasya X. Topal, Elizaveta V. Artemieva, Nuriniso H. Abduloeva, Nikita A. Rysev, Daria A. Barsova, Natalia V. Levchenko, Nikita M. Volkov, Vitaliy V. Egorenkov, Vladimir M. Moiseyenko, Evgeny N. Imyanitov
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 3; Pages: 1870
Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer cells. It is unclear whether the use of ultrasensitive genetic methods may still detect resid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd67cf2ee7392c706f8da4b994ca5076
Autor:
Khristina B Kotiv, Evgeny N. Imyanitov, Anna P. Sokolenko, Alexandr O. Ivantsov, Alexandr A. Romanko, Tatiana I Ermachenkova, Elena V. Preobrazhenskaya, Tatiana V. Gorodnova, Robert V Broyde, Tatiana N. Sokolova, Ilya V. Bizin, Ekaterina Sh Kuligina
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:439-450
Patients with advanced high-grade serous ovarian cancer (HGSOC) are usually treated with paclitaxel and carboplatin; however, predictive markers for this drug combination are unknown. Tumor samples from 71 consecutive HGSOC patients, who received neo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4d163e58996960f7aedff755b2991f4
https://doi.org/10.1007/s00280-021-04301-6
https://doi.org/10.1007/s00280-021-04301-6
Autor:
Vladislav I. Tiurin, Alexandr O. Ivantsov, Grigoriy A. Raskin, Sergey V. Gamajunov, Evgeny N. Suspitsin, Valeriy V. Breder, Svetlana N. Aleksakhina, Evgeny N. Imyanitov, Tatiana N. Sokolova, Barbara Vona, Irina S. Shumskaya, Grigoriy A. Yanus
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 19, Iss 1, Pp 1-7 (2021)
Hereditary Cancer in Clinical Practice
Hereditary Cancer in Clinical Practice
Background Many cancer patients undergo sophisticated laboratory testing, which requires proper interpretation and interaction between different specialists. Case presentation We describe a patient with an extensive family history of cancer, who was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caf74bfd67db434e47f6e5a8358e8c26
https://doaj.org/article/7933bc51ad394e47ad71d5482a37d35d
https://doaj.org/article/7933bc51ad394e47ad71d5482a37d35d